Get access

Homocysteine levels after acute levodopa intake in patients with Parkinson's disease

Authors

  • Thomas Müller MD,

    Corresponding author
    1. Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Gartenstrasse 1, Berlin, Germany
    2. Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, Bochum, Germany
    • Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Gartenstrasse 1, Berlin 13088, Germany
    Search for more papers by this author
  • Wilfried Kuhn MD

    1. Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, Bochum, Germany
    2. Department of Neurology, Leopoldina Hospital, Gustav Adolfstrasse 8, Schweinfurt, Germany
    Search for more papers by this author

  • Potential conflict of interest: Nothing to report.

Abstract

Levodopa (L-dopa) administered with a dopadecarboxylase inhibitor (DDI) increases homocysteine plasma levels. This may support the onset of atherosclerosis-related disorders and neuropsychiatric complications in patients with Parkinson's disease (PD). This homocysteine elevation is considered as long-term effect of chronic L-dopa/DDI treatment. Little is known about the acute effects of L-dopa/DDI intake on homocysteine generation. The objective of this trial was to investigate the relations between L-dopa and homocysteine after acute L-dopa/DDI administration in PD patients with different L-dopa metabolism. Thirty PD patients were divided into groups with superior (I) and less (II) L-dopa absorption after standardized intake of 125 mg L-dopa/benserazide with determination of L-dopa, 3-O-methyl-dopa (3-OMD) and homocysteine in plasma at baseline, 30, 60, and 90 minutes. There was a homocysteine increase in Group I (F = 5; P = 0.005) and a moderate decrease in Group II (F = 4.27; P = 0.01). A rise of 3-OMD (F = 10.51; P < 0.0001) appeared in Group I, but not in Group II (F = 0.91; P = 0.44), accordingly L-dopa accumulation was better in Group I than in Group II. Thus, in conclusion, L-dopa metabolism is an important component for homocysteine elevation after one time L-dopa/DDI administration in PD patients. © 2009 Movement Disorder Society

Ancillary